Off-the-Shelf CAR-T cells take on tough blood cancers
Disease control
Recruiting now
This study tests a new CAR-T therapy made from donor cells, so it's ready to use without waiting for a patient's own cells to be modified. It targets two proteins on cancer cells to lower the chance of the cancer coming back. About 178 adults with relapsed or refractory B-cell ly…
Phase: PHASE1, PHASE2 • Sponsor: AvenCell Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC